Therapies to control gene expression
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
9
NCT06907875
A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
Phase: Phase 1/2
Role: Lead Sponsor
Start: May 8, 2025
Completion: Apr 30, 2032
Loading map...